Citadel Advisors’s Summit Therapeutics SMMT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.18M | Sell |
102,417
-896,323
| -90% | -$19.1M | ﹤0.01% | 2615 |
|
|
2025
Q1 | $19.3M | Buy |
998,740
+811,333
| +433% | +$15.7M | ﹤0.01% | 915 |
|
|
2024
Q4 | $3.34M | Sell |
187,407
-463,426
| -71% | -$8.27M | ﹤0.01% | 2130 |
|
|
2024
Q3 | $14.3M | Buy |
+650,833
| New | +$14.3M | ﹤0.01% | 1049 |
|
|
2024
Q2 | – | Sell |
-5
| Closed | -$21 | – | 6732 |
|
|
2024
Q1 | $21 | Buy |
+5
| New | +$21 | ﹤0.01% | 6035 |
|
|
2023
Q4 | – | Hold |
0
| – | – | – | 6600 |
|
|
2023
Q2 | – | Sell |
-22,381
| Closed | -$39.2K | – | 6417 |
|
|
2023
Q1 | $39.2K | Sell |
22,381
-25,997
| -54% | -$45.5K | ﹤0.01% | 5236 |
|
|
2022
Q4 | $206K | Buy |
+48,378
| New | +$206K | ﹤0.01% | 4681 |
|
|
2022
Q3 | – | Sell |
-56,743
| Closed | -$57K | – | 6642 |
|
|
2022
Q2 | $57K | Buy |
+56,743
| New | +$57K | ﹤0.01% | 5462 |
|
|
2022
Q1 | – | Sell |
-42,593
| Closed | -$115K | – | 7058 |
|
|
2021
Q4 | $115K | Buy |
+42,593
| New | +$115K | ﹤0.01% | 5827 |
|
|
2021
Q3 | – | Sell |
-25,618
| Closed | -$191K | – | 7024 |
|
|
2021
Q2 | $191K | Sell |
25,618
-16,973
| -40% | -$127K | ﹤0.01% | 5610 |
|
|
2021
Q1 | $250K | Buy |
42,591
+26,421
| +163% | +$155K | ﹤0.01% | 5205 |
|
|
2020
Q4 | $76K | Buy |
+16,170
| New | +$76K | ﹤0.01% | 4756 |
|
|
2019
Q2 | – | Sell |
-23,783
| Closed | -$44K | – | 5060 |
|
|
2019
Q1 | $44K | Buy |
23,783
+5,782
| +32% | +$10.7K | ﹤0.01% | 4266 |
|
|
2018
Q4 | $21K | Buy |
+18,001
| New | +$21K | ﹤0.01% | 4259 |
|